Egalet Ltd. is a specialty pharma company focusing on pain management. Based on the Egalet technology, the company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Type
Public
HQ
Wayne, US
Founded
1995
Size (employees)
78 (est)-32%
Website
egalet.com
Egalet was founded in 1995 and is headquartered in Wayne, US

Egalet Office Locations

Egalet has an office in Wayne
Wayne, US (HQ)
460 E Swedesford Rd

Egalet Financials and Metrics

Egalet Financials

Egalet's revenue was reported to be $17 m in FY, 2016
USD

Revenue (Q3, 2017)

6.7 m

Gross profit (Q3, 2017)

5.4 m

Gross profit margin (Q3, 2017), %

81%

Net income (Q3, 2017)

(18.9 m)

EBIT (Q3, 2017)

(15.8 m)

Market capitalization (13-Nov-2017)

35.4 m

Cash (30-Sep-2017)

37.8 m
Egalet's current market capitalization is $35.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

1.9 m22.8 m17 m

Revenue growth, %

1089%(26%)

Cost of goods sold

3.3 m3.7 m

Gross profit

19.6 m13.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

805 k959 k1.7 m2.7 m3.5 m4.7 m5.4 m6.3 m6.7 m

Cost of goods sold

94 k207 k349 k882 k784 k914 k1.3 m1.1 m1.2 m

Gross profit

711 k752 k1.3 m1.8 m2.7 m3.8 m4.1 m5.2 m5.4 m

Gross profit Margin, %

88%78%79%67%77%81%76%83%81%
USDFY, 2014FY, 2015FY, 2016

Cash

52.7 m46.7 m44.4 m

Accounts Receivable

1 m295 k1.1 m

Inventories

3.5 m1.3 m2.5 m

Current Assets

55.1 m150.2 m93.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

69.3 m59.7 m53.9 m57.7 m77.2 m34.2 m35 m46.6 m27 m29.9 m37.8 m

Accounts Receivable

230 k213 k896 k931 k922 k829 k820 k3.9 m5.4 m5.1 m5.6 m

Inventories

2.6 m3.9 m3.6 m2.1 m1.7 m1.5 m1.5 m1.9 m1.4 m

Current Assets

70.4 m61 m69 m114.4 m175.6 m130.4 m108.5 m109.7 m114.9 m97.1 m112.1 m
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (43.2 m)(57.9 m)(90.6 m)

    Depreciation and Amortization

    641 k3 m4.1 m

    Accounts Receivable

    96 k(295 k)(813 k)

    Inventories

    3.9 m(631 k)(1.2 m)
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (24.6 m)(34.7 m)(16.7 m)(33.8 m)(51.2 m)(18.5 m)(42.3 m)(69.3 m)(25.4 m)(51.9 m)(18.9 m)

    Depreciation and Amortization

    311 k466 k631 k1.5 m2.3 m822 k1.7 m2.7 m1.4 m2.6 m

    Accounts Receivable

    (1 k)(1 k)(1 k)(1 k)(534 k)(525 k)(3.6 m)(4.3 m)(4 m)5.6 m

    Inventories

    (40 k)(479 k)(144 k)(300 k)95 k350 k189 k(249 k)1.4 m
      Y, 2017

      Financial Leverage

      -3.6 x
      Show all financial metrics

      Egalet Market Value History

      Egalet's Web-traffic and Trends

      Egalet Online and Social Media Presence

      Egalet News and Updates

      VC-backed Eloxx Pharmaceuticals names CFO

      Israel and Waltham, Massachusetts-based Eloxx Pharmaceuticals Ltd, a developer of treatments that focus on genetic diseases caused by nonsense mutations, has appointed Gregory Weaver as chief financial officer. He is the former CFO at Prometic Life Sciences. The investors included Korea Investment P…

      Egalet Company Life and Culture

      You may also be interested in